/
Financing Transactions for additional details regarding our outstanding indebtedness. For example, it could: increase our vulnerability to general adverse economic and industry conditions; make it more difficult for us to satisfy our other financial obligations; restrict us from making strategic acquisitions or cause us to make non-strategic divestitures; require us to dedicate a substantial po…
$34.50
+$0.89 (+2.65%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-32.18% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 5.0%, steady but not accelerating. Margins contracted 43.0pp, which offsets some of the top-line progress.
ROIC dropped from 5.59% to -17.23%, capital efficiency is deteriorating. Negative free cash flow of -$440M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$3.37B
▲ +5.0% YoY
Net Income (TTM)
-$1.11B
▼ -531.4% YoY
Op. Margin
-31.69%
▼ -43.0pp YoY
ROIC
-16.68%
▼ -22.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$292M
▲ +21.5% YoY
Op. Cash Flow (TTM)
$182M
▲ +1.7% YoY
Net Debt
$2.51B
Cash & Equiv.
$158M
5Y CAGR: +9.7%
Continue Research
Acadia Healthcare Company (ACHC)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in .
On quality, Acadia Healthcare Company scores 19/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 0.1%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Acadia Healthcare Company scores 19 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -31.7% operating margin and a -16.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Acadia Healthcare Company pays a regular dividend of about $0.04 per share per year (typically in quarterly installments), a yield of roughly 0.1% at the current price. Acadia Healthcare Company has grown the dividend at roughly 25.0% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For ACHC's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. you should weigh ACHC's valuation and scores 19/100 on quality (lower-quality). It also yields about 0.1%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.